From pitching to value proposition, here's what you should be thinking about to make your company stand out. Miguel Tovar/University of Houston

During your pitch, investors will be looking to see what your startup's value proposition is. What can you offer that your competitors cannot?

Imagine if you will, your startup develops a watch that can detect when you're about to have a heart attack, and automatically sends an alert with your location to 911.

You've perfected the design and engineering intricacies of the device. It's ready to go out and save lives, and make you tons of money in the process.

Now imagine you can't get this product off the ground because your pitches keep falling flat. Investors don't have confidence in you as an entrepreneur, even if your product is amazing. Remember, you can have an awesome product, but you won't reap any rewards if that awesomeness cannot be expressed to financial gatekeepers.

That's where the art of the pitch matters. Pitching to a venture capitalist might be the most vital part of your startup's success. This is where you express how important your product is or how in demand your services are. This is where you convince investors your product (and you) is worth investing in.

Next, you'll have to determine your company's value proposition, which is the heart of your competitive advantage. This tells venture capitalists why they should invest in your company and not others.

Investors are putting their money and reputation on the line for your company. Their leap of faith has to be as educated as possible. If you can educate them very thoroughly why your startup is different, why it stands out from the rest, investors will feel much more comfortable with their decision to reject other bids in favor of yours.

You don't only need to convince them to choose your company, you also need to convince them that rejecting the other companies won't come back to bite them in the rear. Nobody likes to live with regret, least of all people who put themselves in a position to lose millions of their dollars on a bad decision. The best way to reaffirm an investor's faith in your company is to provide a product or service that is fairly new to the market. New products mean less saturation and higher demand, especially if the product solves a problem or provides a unique function.

There are plenty of toasters on the market, but what about wireless toasters? Outdoors-people everywhere would surely line up to buy that. You're providing a product of real value to a certain sect of people. Your competitive advantage is that your toaster is wireless and portable. That would be your company's value proposition to your investor.

------

This article originally appeared on the University of Houston's The Big Idea.

Rene Cantu is the writer and editor at UH Division of Research.

Hey startups, are you ready to rock and roll? Miguel Tovar/University of Houston

Here's what startups can learn from the Rolling Stones, according to University of Houston researchers

Houston voices

Editor's note: If you think you can't learn some business tips from a rock band, think again. The University of Houston's Big Idea has rounded up a few lessons to be learned from the Rolling Stones — along with advice from UH researchers.

"Start Me Up"

In 1970, the Rolling Stones' long-standing deal with Decca Records expired. This opened a giant door for the band, which I assume they painted black.

Because the band had achieved such success, they were able to form their own record label, dubbed Rolling Stones Records. This was done in an effort to exert more control over their music, not just creatively, but financially. The Stones could now retain the rights over their own music.

Much akin to this move, many startups are launched because entrepreneurs wish to have more control over certain aspects of their technology or product. When asked why he launched his own startup, James Briggs, Ph.D., professor of biochemistry at the University of Houston and president and CFO of Metabocentric Biotechnologies, explained, "Primarily, it was because we felt that development of the technology stood a much better chance if we prosecuted it rather than trying to find a licensing partner."

"Under Your Thumb"

It's no secret that one of the biggest perks of developing your own startup is that you get to be the one to take care of your baby; to oversee the development of your tech through all its stages. You and your co-founders make the decisions on the long road to achieving your vision. Similarly, Professor Briggs and his business partner John Weihua, Ph.D., chairman and CEO of Metabocentric, could now control their company and develop it according to their vision. Had Professor Briggs and Chairman Weihua gone with a licensing partner at such an early stage of their startup, it could have stymied their financial growth.

A licensing entity is not just costly, it handcuffs your startup to dealing with only one licensing partner: them. As a result, you can't generate revenue elsewhere, which you can do if you control your own company.

Much like the Stones' newfound ability to control their own music by not having the tentacles of Decca Records around it, Professor Briggs and Chairman Weihua now had that same ability with their tech; all because they chose to venture out on their own in the infancy of their startup. They were able launch their startup without licensing partners by acquiring non-dilutive funding, which grants startups money without seeking equity in return. So, again, you keep more control of your tech.

"Beast of Burden"

Big record companies have always made it a point to primarily sign acts that are already well established and have a strong fan base locally. Artists in the '60s had to really work hard to gain a big enough name for themselves in their region. Flyers, radio ads, playing weddings, bar mitzvahs, and birthday parties for free just to get your name out there, all the while having to create new material; musicians looking to get signed really had to put in the work.

Before they became household names, the Rolling Stones had garnered a big following in London in 1963. Big enough that the then-gigantic Decca Records noticed and decided to sign them. Record companies sign bands with big local followings because they are more likely to succeed on a grand scale, as opposed to artists who never ventured beyond their garage. In a sense, this was a way for big record companies to reduce the risk of signing an artist that turns out to be a dud.

"Beast of Burden (Remix)"

"Pharmaceutical companies, now, look to small biotech startups to de-risk the lead and approach before they consider partnerships or acquisitions," proclaimed Professor Briggs during his presentation at UH's Startup Pains event. "Pharmaceutical companies don't want to buy failure, they want to buy the success. So they make sure to look for small biotech companies who bring their tech to a point where it is de-risked enough that a partnership suddenly becomes less of a risk to undertake."

Biotech entrepreneurs have to also put in a lot of work to position their startups for potential deals and partnerships with giant pharmaceutical companies. Laying the groundwork for a startup includes searching for investors, virtually begging for money, entering competitions, updating your tech, growing your team, commercializing your product, and staying relevant. "It's a lot of hard work. There will be successes and there will be failures. But in the end, if you stay true to yourselves and your company, there's a greater chance it will pay off."

"Let's Spend the Night Together"

Chemistry, the non-science-y kind, is one of the most overlooked aspects of startups for entrepreneurs. The chemistry a team of individuals have with each other makes for a positive company culture that maintains high morale.

In music, nothing is more important than chemistry. You are whole rather than the sum of a band's parts. Mick Jagger met Keith Richards when they were 16 and became friends because they owned the same Muddy Waters record. Since that time, they have remained best friends. In the studio and on stage, few duos have portrayed the same level of camaraderie and chemistry as Mick and Keith. They met their drummer Charlie Watts at 17, just a year later, and bassist Ronnie Wood in 1975, and lo and behold, they're still all together today.

With a catalog of over 500 songs over 50 years, with the same four band members for the majority of that time, you'll be hard-pressed to find a better paragon of chemistry than the Rolling Stones.

For startups, a strong company culture composed of like-minded individuals working together with chemistry is a prime way to keep your employees motivated, especially when your company is so young, you cannot pay them very much. "You have to remember that most startups are extremely tiny, with 2 to 3 people even, so chemistry is vital. You want to have a culture where you can air your grievances with each other and be honest about your company," Professor Briggs said during the Q & A session of Startup Pains.

"Time Is On Your Side"

A good startup sees its employees working together, functioning as a well-oiled machine, spending long nights together figuring out problems, taking turns ordering Chinese for late meetings, checking each other's work, and learning each other's personalities to more effectively communicate. It takes time. But if the chemistry isn't there naturally, it'll be there once you put in the time to iron out each other's wrinkles.

Investors want to see that your startup has a positive culture before they invest. Similarly, funding entities view company culture as a component that impacts a startup's net profits. If your startup is in disarray, do you really think an intelligent investor is going to want to give you millions of their dollars?

"Even if your tech is great, investors need to see that the company behind the tech is worth the risk."


------

This article originally appeared on the University of Houston's The Big Idea.

Rene Cantu is the writer and editor at UH Division of Research.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Rice Business Plan Competition names startup teams for 2026 event

ready, set, pitch

The Rice Alliance for Technology and Entrepreneurship has announced the 42 student-led teams that will compete in the 26th annual Rice Business Plan Competition this spring.

The highly competitive event, known as one of the world’s largest and richest intercollegiate student startup challenges, will take place April 9-11 on Rice's campus and at the Ion. Teams in this year's competition represent 39 universities from four countries, including one team from Rice and two from the University of Texas at Austin.

Graduate student-led teams from colleges or universities around the world will present their plans before more than 300 angel, venture capital and corporate investors to compete for more than $1 million in prizes. Top teams were awarded $2 million in investment and cash prizes at the 2025 event.

The 2026 invitees include:

  • Alchemll, University of Tennessee - Knoxville
  • Altaris MedTech, University of Arkansas
  • Armada Therapeutics, Dartmouth College
  • Arrow Analytics, Texas A&M University
  • Aura Life Science, Northwestern University
  • BeamFeed, City University of New York
  • BiliRoo, University of Michigan
  • BioLegacy, Seattle University
  • BlueHealer, Johns Hopkins University
  • BRCĒ, Michigan State University
  • ChargeBay, University of Miami
  • Cocoa Potash, Case Western Reserve
  • Cosnetix, Yale University
  • Cottage Core, Kent State University
  • Crack'd Up, University of Wisconsin - Madison
  • Curbon, Princeton University
  • DialySafe, Rice University
  • Foregger Energy Systems, Babson College
  • Forge, University of California, Berkeley
  • Grapheon, University of Pittsburgh
  • GUIDEAIR Labs, University of Washington
  • Hydrastack, University of Chicago
  • Imagine Devices, University of Texas at Austin
  • Innowind Energy Solutions, University of Waterloo (Canada)
  • JanuTech, University of Washington
  • Laetech, University of Toronto (Canada)
  • Lectra Technologies, MIT
  • Legion Platforms, Arizona State University
  • Lucy, University of Pennsylvania
  • NerView Surgical, McMaster University (Canada)
  • Panoptica Technologies, Georgia Tech University
  • PowerHouse, MIT
  • Quantum Power Systems, University of Texas at Austin
  • Routora, University of Notre Dame
  • Sentivity.ai, Virginia Tech
  • Shinra Energy, Harvard University
  • Solid Air Dynamics, RWTH Aachen (Germany)
  • Spine Biotics, University of North Carolina - Chapel Hill
  • The Good Company, Michigan Tech
  • UNCHAIN, Lehigh University
  • VivoFlux, University of Rochester
  • Vocadian, University of Oxford (UK)

This year's group joins more than 910 RBPC alums that have raised more than $6.9 billion in capital, according to Rice.

The University of Michigan's Intero Biosystems, which is developing the first stem cell-driven human “mini gut,” took home the largest investment sum of $902,000 last year. The company also claimed the first-place prize.

Houston suburb ranks as No. 3 best place to retire in Texas

Rankings & Reports

Texas retirees on the hunt for the right place to settle down and enjoy their blissful retirement years will find their haven in the Houston suburb of Pasadena, which just ranked as the third-best city to retire statewide.

A new study conducted by the research team at RetirementLiving.com, "The Best Cities to Retire in Texas," compared the affordability, safety, livability, and healthcare access for seniors across 31 Texas cities with at least 90,000 residents.

Wichita Falls, about 140 miles northwest of Dallas, claimed the top spot as the No. 1 best place to retire in Texas.

The senior living experts said Pasadena has the best healthcare access for seniors in the entire state, and it ranked as the No. 8 most affordable city on the list.

"Taking care of one’s health can be stressful for seniors," the report said. "Harris County, where [Pasadena is] located, has 281.1 primary care physicians per 1,000 seniors — that’s almost 50-fold the statewide ratio of 5.9 per 1,000."

Pasadena ranked 10th overall for its livability, and ranked 25th for safety, the report added.

Meanwhile, Houston proper ranked as the No. 31 best place to retire in Texas, but its livability score was the 7th best statewide.

Seven of the Lone Star State's top 10 best retirement locales are located in the Dallas-Fort Worth Metroplex: Carrollton (No. 2), Plano (No. 4), Garland (No. 5), Richardson (No. 6), Arlington (No. 7), Grand Prairie (No. 8), and Irving (No. 9). McAllen, a South Texas border town, rounded out the top 10.

RetirementLiving said Carrollton has one of the lowest property and violent crime rates per capita in Texas, and it ranked as the No. 5 safest city on the list. About 17 percent of the city's population is aged 65 or older, which is higher than the statewide average of just 14 percent.

The top 10 best place to retire in Texas in 2026 are:

  • No. 1 – Wichita Falls
  • No. 2 – Carrollton
  • No. 3 – Pasadena
  • No. 4 – Plano
  • No. 5 – Garland
  • No. 6 – Richardson
  • No. 7 – Arlington
  • No. 8 – Grand Prairie
  • No. 9 – Irving
  • No. 10 – McAllen
---

This article originally appeared on CultureMap.com.

Rice University lands $18M to revolutionize lymphatic disease detection

fresh funding

An arm of the U.S. Department of Health and Human Services has awarded $18 million to scientists at Rice University for research that has the potential to revolutionize how lymphatic diseases are detected and help increase survivability.

The lymphatic system is the network of vessels all over the body that help eliminate waste, absorb fat and maintain fluid balance. Diseases in this system are often difficult to detect early due to the small size of the vessels and the invasiveness of biopsy testing. Though survival rates of lymph disease have skyrocketed in the United States over the last five years, it still claims around 200,000 people in the country annually.

Early detection of complex lymphatic anomalies (CLAs) and lymphedema is essential in increasing successful treatment rates. That’s where Rice University’s SynthX Center, directed by Han Xiao and Lei Li, an assistant professor of electrical and computer engineering, comes in.

Aided by researchers from Texas Children’s Hospital, Baylor College of Medicine, the University of Texas at Dallas and the University of Texas Southwestern Medical Center, the center is pioneering two technologies: the Visual Imaging System for Tracing and Analyzing Lymphatics with Photoacoustics (VISTA-LYMPH) and Digital Plasmonic Nanobubble Detection for Protein (DIAMOND-P).

Simply put, VISTA-LYMPH uses photoacoustic tomography (PAT), a combination of light and sound, to more accurately map the tiny vessels of the lymphatic system. The process is more effective than diagnostic tools that use only light or sound, independent of one another. The research award is through the Advanced Research Projects Agency for Health (ARPA-H) Lymphatic Imaging, Genomics and pHenotyping Technologies (LIGHT) program, part of the U.S. HHS, which saw the potential of VISTA-LYMPH in animal tests that produced finely detailed diagnostic maps.

“Thanks to ARPA-H’s award, we will build the most advanced PAT system to image the body’s lymphatic network with unprecedented resolution and speed, enabling earlier and more accurate diagnosis,” Li said in a news release.

Meanwhile, DIAMOND-P could replace the older, less exact immunoassay. It uses laser-heated vapors of plasmonic nanoparticles to detect viruses without having to separate or amplify, and at room temperature, greatly simplifying the process. This is an important part of greater diagnosis because even with VISTA-LYMPH’s greater imaging accuracy, many lymphatic diseases still do not appear. Detecting biological markers is still necessary.

According to Rice, the efforts will help address lymphatic disorders, including Gorham-Stout disease, kaposiform lymphangiomatosis and generalized lymphatic anomaly. They also could help manage conditions associated with lymphatic dysfunction, including cancer metastasis, cardiovascular disease and neurodegeneration.

“By validating VISTA-LYMPH and DIAMOND-P in both preclinical and clinical settings, the team aims to establish a comprehensive diagnostic pipeline for lymphatic diseases and potentially beyond,” Xiao added in the release.

The ARPA-H award funds the project for up to five years.